Cardiff Oncology, Inc.
CRDF
$1.79
-$0.03-1.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -13.30% | -27.29% | -17.89% | -3.61% | 40.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -13.30% | -27.29% | -17.89% | -3.61% | 40.16% |
| Cost of Revenue | 43.05% | -86.32% | -81.32% | -87.02% | -94.94% |
| Gross Profit | -82.50% | 87.51% | 82.62% | 88.65% | 96.98% |
| SG&A Expenses | 13.96% | 16.76% | 12.16% | 2.11% | -4.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.44% | 15.09% | 21.16% | 17.34% | 7.48% |
| Operating Income | -0.64% | -15.72% | -21.74% | -17.63% | -7.13% |
| Income Before Tax | -0.92% | -17.31% | -24.87% | -21.44% | -9.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.92% | -17.31% | -24.87% | -21.44% | -9.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.92% | -17.31% | -24.87% | -21.44% | -9.63% |
| EBIT | -0.64% | -15.72% | -21.74% | -17.63% | -7.13% |
| EBITDA | -0.72% | -15.94% | -22.02% | -17.82% | -7.18% |
| EPS Basic | 28.24% | 15.98% | 3.48% | -3.84% | -3.20% |
| Normalized Basic EPS | 28.23% | 15.96% | 3.45% | -3.86% | -3.19% |
| EPS Diluted | 28.24% | 15.98% | 3.48% | -3.84% | -3.20% |
| Normalized Diluted EPS | 28.23% | 15.96% | 3.45% | -3.86% | -3.19% |
| Average Basic Shares Outstanding | 40.28% | 40.38% | 30.90% | 18.87% | 6.65% |
| Average Diluted Shares Outstanding | 40.28% | 40.38% | 30.90% | 18.87% | 6.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |